ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AFMD Affimed NV

5.425
0.125 (2.36%)
After Hours
Last Updated: 21:19:01
Delayed by 15 minutes
Share Name Share Symbol Market Type
Affimed NV NASDAQ:AFMD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.125 2.36% 5.425 5.31 5.85 5.51 5.10 5.42 82,327 21:19:01

Affimed to Present at Upcoming Investor Conferences

02/09/2020 11:30am

GlobeNewswire Inc.


Affimed NV (NASDAQ:AFMD)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Affimed NV Charts.

 

Heidelberg, Germany, September 2, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the company’s management will participate in the following investor conferences during the month of September 2020:

2020 Wells Fargo Virtual Healthcare Conference (September 9-10, 2020) Date: Wednesday, September 9, 2020 Presentation Time: Fireside chat with Dr. Jim Birchenough at 8:00 a.m. Eastern Time Citi’s 15th Annual BioPharma Virtual Conference (September 8-11, 2020) Date: Wednesday, September 10, 2020 Affimed will host meetings with investors at the conference

Cantor Fitzgerald Virtual Global Healthcare Conference 2020 (September 15-17, 2020)Date: Thursday, September 17, 2020 Presentation Time: 12:40 p.m. Eastern Time Oppenheimer Fall Healthcare Life Sciences and Med Tech Summit (September 21-23, 2020) Date: Monday, September 21, 2020 Presentation Time: 3:20 p.m. Eastern Time Location: Virtual

Webcasts of each presentation may be accessed on Affimed’s website at https://www.affimed.com/investors/webcasts_cp/. For more information on the conferences or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at (917) 436-8102.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

Investor & Media Contact:

Alex Fudukidis Head of Investor Relations E-Mail: a.fudukidis@affimed.com Tel.: +1 (917) 436-8102

 

1 Year Affimed NV Chart

1 Year Affimed NV Chart

1 Month Affimed NV Chart

1 Month Affimed NV Chart

Your Recent History

Delayed Upgrade Clock